Travoprost: A potent ocular hypotensive agent

Drugs of Today

Volumn 39, Issue 1, 2003, Pages 61-74

  Al Jazzaf, Adel M ^a   DeSantis, Louis ^a   Netland, Peter A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTERASE; LATANOPROST; PRODRUG; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST;

CLINICAL TRIAL; CORNEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STORAGE; DRUG STRUCTURE; EYE COLOR; EYELASH; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; RECEPTOR AFFINITY; REVIEW;

ANIMALS; CLINICAL TRIALS; CLOPROSTENOL; HUMANS; OCULAR HYPOTENSION;

EID: 0037234313     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.1.799432     Document Type: Review

References (26)

1. Quigley, H.A. Number of people with glaucoma worldwide. Br J Ophthalmol 1996, 80: 389-93.
2. Quigley, H.A., Vitale S. Models of glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997, 38: 83-91.
3. Sharif, N.A., Williams, G.W., Kelly, C.R. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 2001, 432: 211-3.
4. Hellberg, M., Sallee, V., McLaughlin, M. et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocular Pharmacol Ther 2001, 17: 421-32.
5. Sorbera, L., Castaner, J. Travoprost-antiglaucoma prostaglandin FP agonist. Drugs Future 2000, 25: 41-5.
6. Sharif, N.A., Kelly, C.R., Crider, J.Y. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocular Pharmacol and Therap 2002, 18: 313-24.
7. 3H]β-(±)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP Receptor. J Pharm Pharmacol 1999, 51: 685-94.
8. Coleman, R.A., Kennedy, I., Humphrey, P.P.A., Bunce, K., Lumley, P. Prostanoids and their receptors. In: Comprehensive Medicinal Chemistry, Vol. 3. Emmett, J.C., Hansch, C., Sammes, P.G., Taylor, J.B. (Eds.). Pergamon Press: Oxford 1990.
9. Hellberg, M.R., McLaughlin, M.A., Sharif, N.A. et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol 2002, 47 (Suppl. 1): S13-33.
10. Griffin, B., Williams, G., Crider, J., Sharif, N.A. FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: A pharmacological study. Pharmacol Exp Ther 1997, 281: 845-54.
11. Weinreb, R.N., Kashiwagi, K., Kashiwagi, F., Tsukahara, S., Lindsey, J.D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997, 38: 2772-80.
12. Kim J-W., Lindsey, J.D., Wang, N., Weinreb, R.N. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 2001, 42: 1514-21.
13. 3H] prostaglandin F2 to EP3 and FP prostaglandin receptor binding sites in corpus luteum: Characterization and correlation with functional data. J Pharmacol Exp Therap 1998, 286: 1094-102.
14. Woodword, D.F., Chen, J. Endothelium dependent, nitric oxide (NO) mediated vasorelaxation substantially contributes to ocular surface hyperemic responses produced by prostaglandin F2" (PGF2") and its analogs. Invest Ophthalmol Visual Sci 1999, 40 (Suppl.): Abst 912.
15. Hellberg, M., Sallee, V., McLaughlin, M., et al. Preclinical efficacy of AL-6221, a potent and selective FP prostaglandin agonist. Invest Ophthalmol Vis Sci 1998, 39 (Suppl.): Abst 1961.
16. Dean, T.R., Barnes, G.E., Li, B., Chandler, M.L. Improvement of optic nerve head blood flow after one-week topical treatment with travoprost (AL-6221) in the rabbit. Invest Ophthalmmol Visual Sci 1999, 40 (Suppl.): Abst 2688.
17. Robin, A., Faulkner, R., Curtis. et al. Safety and pharmacokinetics of travoprost, a potent prostaglandin F(FP) receptor agonist, in patients with renal and hepatic impairment. ARVO 2002,. Abst 4106.
18. Netland, P., Landry, T., Kenneth, S. et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001, 132: 472-84.
19. Goldberg, I., Cunha-Vaz, J., Jakoben, J-E., Nordmann, J-P., Trost, E., Sullivan, E.K. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001, 10: 414-22.
20. Fellman, R., Sullivan, E., Ratliff, M. et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated IOP. Ophthalmology 2002, 109: 998-1008.
21. Orengo-Nania, S., Landry, T., Vontress, M., Silver, L., Weiner, A., Davis, A.A. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001, 132: 860-8.
22. Schenker, H., Williams, L., Goode, S. et al. Iris pigmentation changes following treatment with travoprost or latanoprost in patients with openangle glaucoma or ocular hypertension. ARVO 2002, Abst 3431.
23. Hellberg, M., Airy, S., Chiou, J. et al. Unique polypropylene packaging system for Travatan® minimizes loss to the container. ARVO (2002, Abst 2318.
24. Weiner, A., Kabra, B., Sternitzke, K. et al. Travatan® is stable to extremes of temperature and light exposure. ARVO 2002; Abst 2307.
25. Garadi, R., Silver, L., Landry, T., Turner, F.D. Travoprost: A new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure. Invest Opthalmol Vis Sci 1999, 40: S831.
26. Dubiner, H. Travatan administration results in effective diurnal reduction in intraocular pressure over 36 h and lower pressure up to 3.5 days without further dosing. ARVO 2002; Abst 1066.